We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 31 mei 2018

The Lancet: [News] Responses to carboplatin in BRCA1/2-mutated breast cancer

[News] Responses to carboplatin in BRCA1/2-mutated breast cancer
Women with metastatic, triple-negative breast cancer who have BRCA1 or BRCA2 mutations are more likely to respond to carboplatin as docetaxel, according to a new study.
Read more

[Articles] Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Ribociclib plus endocrine therapy improved progression-free survival compared with placebo plus endocrine therapy, and had a manageable safety profile in patients with premenopausal, HR-positive, HER2-negative, advanced breast cancer. The combination could represent a new first-line treatment option for these patients.
Read more

[Comment] Ribociclib in premenopausal women with advanced breast cancer
Inhibition of cell-cycle progression using inhibitors of cyclin-dependent kinases (CDKs) 4 and 6 is an effective treatment strategy in hormone-receptor-positive breast cancer. Three inhibitors of CDKs 4 and 6—palbociclib, ribociclib, and abemaciclib—are approved by the US Food and Drug Administration for treatment of advanced breast cancer. The approval for palbociclib and abemaciclib, based on subgroup analyses from the PALOMA-31 and MONARCH-22 trials, includes premenopausal and perimenopausal patients provided that endocrine therapy is combined with ovarian suppression using a gonadotropin-releasing hormone (GnRH) analogue.
Read more

[News] Addition of mitoxantrone and prednisone to ADT
Addition of mitoxantrone plus prednisone to adjuvant androgen-deprivation therapy (ADT), which is hypothesised to reduce mortality in patients with high-risk prostate cancer after radical prostatectomy, does not improve overall survival, according to the results of a recent study.
Read more

[Articles] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses.
Read more